» Articles » PMID: 18692524

CXCL12/CXCR4 Signaling Promotes Human Thymic Dendritic Cell Survival Regulating the Bcl-2/Bax Ratio

Overview
Journal Immunol Lett
Date 2008 Aug 12
PMID 18692524
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

CXCL12, a member of the chemokine CXC subfamily, and its physiologic receptor CXCR4 are essential for the development of various organs during embryonic development and are also involved in the control of cell survival, proliferation and migration in adult tissues. In the human thymus, CXCL12 is produced by epithelial cells located in the subcapsular and medullary regions and CXCR4 is expressed in different thymocyte subpopulations. Several results have demonstrated that CXCL12/CXCR4 signaling participates in different intrathymic processes including the control of human precursor cell survival and proliferation, and the exit of mature thymocytes to the periphery. In this study, we show that CXCL12 is also produced by human thymic dendritic cells (DCs), most of which express CXCR4 receptor. The addition of exogenous CXCL12 significantly inhibited the serum depletion-induced apoptosis in thymic DCs, and the treatment with neutralizing antibodies against CXCL12 or CXCR4 decreased their survival. The survival-promoting effect of CXCL12 was mediated by the up-regulation of Bcl-2 protein expression and the concomitant down-regulation of Bax protein expression. The higher viability of thymic DCs also enhanced their allostimulatory capacity. Taken together, the results suggest a new function of CXCL12 in the human thymus controlling the survival and functionality of thymic DCs.

Citing Articles

An Organotypic Human Lymph Node Model Reveals the Importance of Fibroblastic Reticular Cells for Dendritic Cell Function.

Morrison A, Mikula A, Spiekstra S, de Kok M, Affandi A, Roest H Tissue Eng Regen Med. 2023; 21(3):455-471.

PMID: 38114886 PMC: 10987465. DOI: 10.1007/s13770-023-00609-x.


Effects of invivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates.

Rossi A, Tremblay S, Castro-Rojas C, Burg A, Roskin K, Gehman J Am J Transplant. 2023; 23(6):759-775.

PMID: 36871629 PMC: 10259505. DOI: 10.1016/j.ajt.2023.02.022.


Plasma cell biology: Foundations for targeted therapeutic development in transplantation.

Rossi A, Alloway R, Hildeman D, Woodle E Immunol Rev. 2021; 303(1):168-186.

PMID: 34254320 PMC: 8387355. DOI: 10.1111/imr.13011.


WHIM Syndrome: from Pathogenesis Towards Personalized Medicine and Cure.

Heusinkveld L, Majumdar S, Gao J, McDermott D, Murphy P J Clin Immunol. 2019; 39(6):532-556.

PMID: 31313072 PMC: 6698215. DOI: 10.1007/s10875-019-00665-w.


Adaptive Immunodeficiency in WHIM Syndrome.

Majumdar S, Murphy P Int J Mol Sci. 2018; 20(1).

PMID: 30577453 PMC: 6337672. DOI: 10.3390/ijms20010003.